Core Viewpoint - InMode's management believes that the multi-year downturn in demand is stabilizing, with expectations for flat revenue in 2026 after two years of decline, while focusing on building infrastructure to support recovery, particularly in North America [4][6]. Organizational Changes - The company has restructured its North American organization by appointing a new president and adding two vice presidents, creating a "presidential suite" to enhance execution [1]. - A bifurcation of the salesforce has occurred to focus on wellness segments, including dedicated teams for eye care and women's and men's health [6][5]. Market Demand and Strategy - InMode anticipates that demand for aesthetic procedures will eventually return, although current softness is widespread and not limited to energy-based devices [2]. - The company is expanding its offerings beyond aesthetics into women's health and eye care, with plans to pursue ENT as a potential new area [7][8]. Product Development - InMode is broadening its product line to include lasers, aiming to become a "one-stop shop" for energy-based devices, despite facing gross margin pressure due to the commodity nature of lasers [9][10][11]. - The company has launched a Pico laser and plans to introduce an Erbium laser later this year, with a new version of Morpheus8 expected toward year-end [16][17]. Financial Outlook - The CFO indicated that patient demand is a significant headwind, with higher interest rates impacting capital equipment sales, but the focus remains on stabilizing revenue and improving margins [2][4][14]. - InMode is evaluating various capital allocation strategies, including share buybacks, dividends, and potential M&A to support expansion into new areas [12]. Market Dynamics - The company recognizes that margin performance is heavily influenced by product mix, particularly in North America, which is its most profitable region [14]. - InMode is monitoring external factors such as tariffs, which could impact margins positively if resolved [14].

Core Viewpoint - InMode is facing significant operational challenges due to geopolitical instability in Israel, affecting its capacity and logistics, while also outlining plans for capital return and product strategy amidst these difficulties [3][5][10]. Operational Challenges - The company is currently operating at approximately 60% capacity due to security-related shutdowns and employee availability issues caused by school closures [2][5]. - Shipping logistics have become increasingly difficult and expensive, with air freight severely constrained and reliance on sea freight that can cost up to five times more [1][5]. - InMode has built a "safety inventory" of finished goods and components, but this may not last if disruptions continue for another six months [1][5]. Capital Return and Financial Position - InMode has repurchased about $508 million in shares to date and expects total buybacks to reach around $600 million, including a new authorization for 6.4 million shares valued at approximately $85–$90 million [4][6]. - The company maintains a cash position of about $550 million, which could decrease to around $450 million after completing the current repurchase program [7][4]. Demand Trends - Demand for aesthetic procedures is stabilizing, with the company not experiencing growth but also not declining, particularly in disposable products [8][10]. - Financing conditions for platform purchases are challenging, with leasing interest rates around 14% to 15% for five years, making leasing companies hesitant to take risks [9][10]. Installed Base and Organizational Changes - InMode has approximately 30,000 systems worldwide, increasing its installed base by around 5,000 systems annually [11]. - The company has unified its North American operations under a single president, replacing around 30 salespeople and monitoring for further adjustments [12][13]. Product Strategy - InMode is expanding its product offerings to include laser technologies, complementing its existing RF-based procedures, and is developing new laser platforms [14]. - The company is focusing on its Envision platform for dry eye treatment and is pursuing FDA approval for a study using RF technology [15]. - InMode is interested in larger acquisitions valued between $500 million to $1 billion, particularly in the injectables market, and sees significant growth potential in Asia [15][14]. Gross Margin and Market Conditions - Gross margin performance is influenced by product and geographic mix, with a shift towards lower-margin laser devices impacting overall margins [16]. - The company believes that demand for aesthetic procedures will eventually recover, which could support margin improvement [17].

Summary of InMode (INMD) FY Conference Call - August 12, 2025 Company Overview - InMode is a leading player in the global energy-based aesthetic treatments market [1] Key Financial Performance - Q2 performance was described as "okay," not as strong as hoped, but not a terrible quarter [3] - There was a decline in the U.S. market, offset by record performance in Europe and growth in Asia Pacific [4] - Continued challenges include low patient demand and higher interest rates affecting capital equipment investments [5] - Q2 guidance was lowered by $5 million due to underperformance in both Q1 and Q2 [7] Market Dynamics - The revenue mix has shifted to approximately 50% from the U.S. and 50% from outside the U.S., compared to a previous 65% U.S. and 35% OUS [15] - The U.S. market is seen as more profitable, and recovery in consumer confidence is anticipated to improve this mix [15] - The entire energy-based device industry is facing similar challenges, with declines in sales reported across competitors [17] Product Development and Trends - There is an increasing trend in non-invasive platform treatments, particularly combination treatments like Morpheus8 with CO2 laser procedures [10] - Demand for new platforms like Optimus Max and Ignite has been weaker than expected due to economic conditions [19] - A new wellness platform for erectile dysfunction is set for a full launch soon, with current sales based on FDA clearance for improved blood circulation [23] Research and Development Strategy - InMode plans to continue introducing new products in both aesthetic and wellness areas, focusing on minimally invasive and non-invasive procedures [26] - The company is exploring the development of products targeting cheaper, non-invasive procedures [26] Management and Organizational Changes - Changes in the management structure were made to adapt to accelerated growth, including promotions and new hires in various regions [28] - The sales team is being reorganized to create specialties for different product lines [31] Capital Allocation Strategy - InMode has repurchased 27% of the company for approximately $400 million and is considering further buybacks, dividends, and M&A opportunities [36][37] - The company is open to various cash allocation strategies to support future growth [37] Tariff Impact - The company estimates an average tariff impact of 10%, which could affect gross margins by 2-3% annually [39] Conclusion - InMode is navigating a challenging market environment but remains focused on product innovation, strategic management changes, and capital allocation to drive future growth [1][28][37]